Small cap rare disease biotechs jump after peer Amicus gets FDA nod

Shares of small-cap biotech companies involved in rare disease cures are trading higher after peer Amicus Therapeutics announced that the FDA informed the company that it may now submit an NDA for Fabry disease treatment migalastat.